Irish-based Trinity Biotech plc has announced its latest acquisition in the medical diagnostic products sector. The company develops, manufactures, and markets medical diagnostic products for clinical laboratory and point-of-care (POC) segments of the diagnostic market across the globe, including in the Americas, Africa, Asia, and Europe. Trinity Biotech plc offers a wide range of clinical laboratory products, including diagnostic tests and instrumentation designed to detect various infectious diseases such as Lyme disease, sexually transmitted diseases such as syphilis and herpes, SARS-CoV-2, and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella, and other viral pathogens. Additionally, the company's products feature in-vitro diagnostic testing for haemoglobin A1c, which can be used to monitor and diagnose diabetes, identify those who are at a risk of developing diabetes. Further, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats. Trinity Biotech plc also sells raw materials to the life sciences industry and research institutes. The company serves various customers, including public health authorities, non-governmental organizations, clinical and reference laboratories, through its direct sales force and network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and has its headquarters in Bray, Ireland.
Trinity Biotech plc's ticker is TRIB
The company's shares trade on the NASDAQ stock exchange
They are based in Bray, Ireland
There are 501-1000 employees working at Trinity Biotech plc
It is https://www.trinitybiotech.com/
Trinity Biotech plc is in the Healthcare sector
Trinity Biotech plc is in the Biotechnology industry
The following five companies are Trinity Biotech plc's industry peers: